MCID: ORL007
MIFTS: 57

Oral Cavity Cancer

Categories: Cancer diseases, Gastrointestinal diseases, Oral diseases

Aliases & Classifications for Oral Cavity Cancer

MalaCards integrated aliases for Oral Cavity Cancer:

Name: Oral Cavity Cancer 12 15 17
Malignant Neoplasm of Floor of Mouth 12 33
Malignant Neoplasm of Anterior Portion of Floor of Mouth 12
Malignant Neoplasm of Lateral Portion of Floor of Mouth 12
Malignant Neoplasm of Lateral Floor of Mouth 12
Malignant Tumor of Anterior Floor of Mouth 12
Malignant Tumor of Lateral Floor of Mouth 12
Malignant Tumor of the Floor of the Mouth 12
Malignant Tumor of Floor of Mouth 6
Malignant Neoplasm of Mouth 72
Oral Cavity Carcinoma 72

Classifications:



External Ids:

Disease Ontology 12 DOID:8618
NCIt 50 C9318
UMLS 72 C0151546 C0153368 C0153369 more

Summaries for Oral Cavity Cancer

Disease Ontology : 12 A gastrointestinal system cancer that is located in the oral cavity.

MalaCards based summary : Oral Cavity Cancer, also known as malignant neoplasm of floor of mouth, is related to oral cancer and squamous cell carcinoma. An important gene associated with Oral Cavity Cancer is PIK3CA (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha), and among its related pathways/superpathways are ERK Signaling and Akt Signaling. The drugs Nicotine and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include lymph node, tongue and breast, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Related Diseases for Oral Cavity Cancer

Diseases in the Oral Cavity Cancer family:

Oral Cavity Carcinoma in Situ

Diseases related to Oral Cavity Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 117)
# Related Disease Score Top Affiliating Genes
1 oral cancer 32.2 GSTM1 EGFR CYP1A1
2 squamous cell carcinoma 31.2 VEGFA PTEN PIK3CA ERBB2 EGFR CYP1A1
3 adenoid cystic carcinoma 30.7 VEGFA PTEN PIK3CA ERBB2
4 nasopharyngeal carcinoma 30.0 VEGFA PIK3CA GSTM1 EGFR
5 esophageal cancer 29.7 VEGFA SOX2 PTEN PIK3CA GSTM1 ERCC1
6 lip and oral cavity cancer 12.6
7 oral squamous cell carcinoma 11.6
8 salivary gland carcinoma 11.3
9 breast intraductal proliferative lesion 11.0 ERBB2 EGFR
10 geographic tongue 10.9 VEGFA TNFRSF10B EGFR
11 breast carcinoma in situ 10.9 VEGFA ERBB2 EGFR
12 pharynx cancer 10.8 VEGFA GSTM1 EGFR
13 esophageal disease 10.8 ERBB2 EGFR ALDH2
14 primary peritoneal carcinoma 10.8 VEGFA ERCC1 ERBB2 EGFR
15 nervous system cancer 10.8 VEGFA PTEN EGFR
16 breast squamous cell carcinoma 10.8 PIK3CA ERBB2 EGFR
17 colonic disease 10.8 VEGFA EGFR EDNRB
18 stomach disease 10.8 VEGFA ERBB2 EGFR
19 adenosquamous lung carcinoma 10.8 PIK3CA ERBB2 EGFR
20 breast scirrhous carcinoma 10.8 ERBB2 EGFR
21 acneiform dermatitis 10.7 PIK3CA ERBB2 EGFR CYP1A1
22 progesterone-receptor negative breast cancer 10.7 ERBB2 EGFR
23 ovary epithelial cancer 10.7 VEGFA PIK3CA ERBB2
24 breast disease 10.7 VEGFA SOD2 ERBB2 CYP1A1 BAX
25 malignant ovarian surface epithelial-stromal neoplasm 10.7 VEGFA PIK3CA ERBB2
26 cerebrum cancer 10.7 VEGFA SOX2 PTEN EGFR
27 supratentorial cancer 10.7 VEGFA SOX2 PTEN EGFR
28 ovarian cancer 1 10.7 VEGFA PIK3CA ERBB2
29 female reproductive system disease 10.7 VEGFA PTEN ERBB2 EGFR
30 central nervous system cancer 10.7 VEGFA SOX2 PTEN EGFR
31 reproductive system disease 10.7 VEGFA PTEN ERBB2 EGFR
32 ovary adenocarcinoma 10.7 PIK3CA ERBB2 BAX
33 serous cystadenocarcinoma 10.7 VEGFA PIK3CA ERBB2
34 endometrial adenocarcinoma 10.7 VEGFA PTEN ERBB2 EGFR
35 cystadenocarcinoma 10.7 VEGFA PIK3CA ERBB2
36 estrogen-receptor positive breast cancer 10.7 PIK3CA ERBB2 EGFR
37 intestinal disease 10.7 VEGFA PIK3CA EGFR EDNRB
38 endocrine gland cancer 10.7 VEGFA PTEN ERBB2 EGFR
39 adult hepatocellular carcinoma 10.7 PIK3CA CASP8
40 grade iii astrocytoma 10.7 VEGFA PTEN EGFR
41 mucinous stomach adenocarcinoma 10.7 VEGFA PTEN
42 sister chromatid exchange, frequency of 10.6 GSTM1 ALDH2
43 acute t cell leukemia 10.6 PTEN CASP8 BAX
44 ovarian serous cystadenocarcinoma 10.6 PIK3CA ERBB2 BAX
45 carcinosarcoma 10.6 PTEN PIK3CA ERBB2
46 thyroid hurthle cell adenoma 10.6 PTEN PIK3CA
47 uterine anomalies 10.6 VEGFA PTEN PIK3CA ERBB2
48 uterine carcinosarcoma 10.5 PTEN PIK3CA ERBB2 EGFR
49 adenocarcinoma 10.5 VEGFA PTEN PIK3CA ERBB2 EGFR
50 gastrointestinal system cancer 10.5 VEGFA PTEN PIK3CA ERBB2 EGFR

Comorbidity relations with Oral Cavity Cancer via Phenotypic Disease Network (PDN):


Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Oral Cavity Cancer:



Diseases related to Oral Cavity Cancer

Symptoms & Phenotypes for Oral Cavity Cancer

GenomeRNAi Phenotypes related to Oral Cavity Cancer according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.77 BAX CASP8 ERCC1 FADD MCL1 PTEN
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.77 BAX CASP8 ERCC1 FADD MCL1 PTEN
3 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.55 EGFR ERBB2 GSTM1 PTEN VEGFA
4 Decreased viability with paclitaxel GR00179-A-1 9.26 EGFR ERBB2 FADD
5 Decreased viability with paclitaxel GR00179-A-3 9.26 EGFR

MGI Mouse Phenotypes related to Oral Cavity Cancer:

46 (show all 25)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.51 ALDH2 BAX CASP8 CYP1A1 EDNRB EGFR
2 homeostasis/metabolism MP:0005376 10.49 ALDH2 BAX CASP8 CYP1A1 EDNRB EGFR
3 cellular MP:0005384 10.48 ALDH2 BAX CASP8 EDNRB EGFR ERBB2
4 cardiovascular system MP:0005385 10.46 ALDH2 CASP8 CYP1A1 EDNRB EGFR ERBB2
5 endocrine/exocrine gland MP:0005379 10.46 ALDH2 BAX CASP8 CYP1A1 EDNRB EGFR
6 mortality/aging MP:0010768 10.45 ALDH2 BAX CASP8 CYP1A1 EDNRB EGFR
7 immune system MP:0005387 10.42 ALDH2 BAX CASP8 CYP1A1 EDNRB EGFR
8 hematopoietic system MP:0005397 10.41 ALDH2 BAX CASP8 CYP1A1 EDNRB EGFR
9 behavior/neurological MP:0005386 10.4 ALDH2 BAX EDNRB ERBB2 ERCC1 GDF15
10 embryo MP:0005380 10.37 CASP8 EDNRB EGFR ERBB2 ERCC1 FADD
11 integument MP:0010771 10.35 ALDH2 CASP8 EDNRB EGFR ERBB2 ERCC1
12 muscle MP:0005369 10.35 ALDH2 BAX CASP8 EDNRB EGFR ERBB2
13 nervous system MP:0003631 10.31 ALDH2 BAX CASP8 EDNRB EGFR ERBB2
14 neoplasm MP:0002006 10.27 ALDH2 BAX CASP8 EDNRB EGFR ERBB2
15 liver/biliary system MP:0005370 10.25 ALDH2 CASP8 CYP1A1 EGFR ERCC1 FADD
16 digestive/alimentary MP:0005381 10.2 EDNRB EGFR ERBB2 FADD PTEN SOX2
17 adipose tissue MP:0005375 10.17 EGFR ERCC1 GDF15 PIK3CA PTEN SOD2
18 limbs/digits/tail MP:0005371 10.07 ALDH2 BAX EDNRB EGFR ERBB2 PTEN
19 normal MP:0002873 10.06 CYP1A1 EGFR ERBB2 LIN28B MCL1 PTEN
20 renal/urinary system MP:0005367 10.06 ALDH2 BAX CASP8 EDNRB EGFR ERCC1
21 reproductive system MP:0005389 10 ALDH2 BAX EGFR ERBB2 ERCC1 MCL1
22 pigmentation MP:0001186 9.85 ALDH2 EDNRB EGFR PTEN SOD2 SOX2
23 respiratory system MP:0005388 9.81 BAX CASP8 EDNRB EGFR ERBB2 PTEN
24 skeleton MP:0005390 9.73 ALDH2 BAX EDNRB EGFR ERBB2 ERCC1
25 vision/eye MP:0005391 9.28 ALDH2 BAX EDNRB EGFR PIK3CA PTEN

Drugs & Therapeutics for Oral Cavity Cancer

Drugs for Oral Cavity Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 143)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nicotine Approved Phase 4 54-11-5 942 89594
2
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
3
Bupropion Approved Phase 4 34841-39-9, 34911-55-2 444
4 Peripheral Nervous System Agents Phase 4
5 Autonomic Agents Phase 4
6 Neurotransmitter Agents Phase 4
7 Psychotropic Drugs Phase 4
8 Liver Extracts Phase 4
9 Cholinergic Agents Phase 4
10 Nicotinic Agonists Phase 4
11 Central Nervous System Stimulants Phase 4
12 Antidepressive Agents Phase 4
13 Cytochrome P-450 CYP2D6 Inhibitors Phase 4
14 Antidepressive Agents, Second-Generation Phase 4
15 Cytochrome P-450 Enzyme Inhibitors Phase 4
16 Dopamine Agents Phase 4
17 Neurotransmitter Uptake Inhibitors Phase 4
18 Dopamine Uptake Inhibitors Phase 4
19
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
20
Pilocarpine Approved, Investigational Phase 2, Phase 3 92-13-7, 54-71-7 5910
21
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 50-18-0, 6055-19-2 2907
22
Dexamethasone Approved, Investigational, Vet_approved Phase 2, Phase 3 50-02-2 5743
23
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2, Phase 3 1177-87-3
24
Celecoxib Approved, Investigational Phase 2, Phase 3 169590-42-5 2662
25 Muscarinic Agonists Phase 2, Phase 3
26 Analgesics Phase 2, Phase 3
27 Alkylating Agents Phase 2, Phase 3
28 Gastrointestinal Agents Phase 2, Phase 3
29 Cyclooxygenase Inhibitors Phase 2, Phase 3
30 Anti-Inflammatory Agents, Non-Steroidal Phase 2, Phase 3
31 Analgesics, Non-Narcotic Phase 2, Phase 3
32 Anti-Inflammatory Agents Phase 2, Phase 3
33 Antirheumatic Agents Phase 2, Phase 3
34 Antineoplastic Agents, Alkylating Phase 2, Phase 3
35 Hormone Antagonists Phase 2, Phase 3
36 Antiemetics Phase 2, Phase 3
37 Cyclooxygenase 2 Inhibitors Phase 2, Phase 3
38 HIV Protease Inhibitors Phase 2, Phase 3
39 Angiogenesis Inhibitors Phase 2, Phase 3
40 glucocorticoids Phase 2, Phase 3
41 Hormones Phase 2, Phase 3
42
protease inhibitors Phase 2, Phase 3
43 Angiogenesis Modulating Agents Phase 2, Phase 3
44 Anti-Bacterial Agents Phase 2, Phase 3
45 Anti-Infective Agents Phase 2, Phase 3
46 Antineoplastic Agents, Hormonal Phase 2, Phase 3
47 BB 1101 Phase 2, Phase 3
48 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3
49
Amifostine Approved, Investigational Phase 2 20537-88-6 2141
50
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124

Interventional clinical trials:

(show top 50) (show all 101)
# Name Status NCT ID Phase Drugs
1 Comparing the Lozenge to the Patch for Smoking Cessation Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
2 Enhancing Tobacco Use Treatment for African American Light Smokers Completed NCT00666978 Phase 4 bupropion hydrochloride
3 RANDOMIZED TRIAL OF NEOADJUVANT CHEMOTHERAPY AND SURGERY +/- RADIOTHERAPY VERSUS SURGEERY +/- RADIOTHERAPY IN OPERABLE SQUAMOUS CELL CARCINOMA OF THE ORAL CAVITY Unknown status NCT00002747 Phase 3 cisplatin;fluorouracil
4 A Phase III Study to Test the Efficacy and Safety of GM-CSF to Reduce the Severity and Duration of Mucosal Injury and Pain (Mucositis) Associated With Curative Radiation Therapy in Head and Neck Cancer Patients Completed NCT00008398 Phase 3
5 Phase III Placebo-Controlled Chemoprevention Study of Oral Cavity Squamous Cell Carcinoma Patients Completed NCT00201279 Phase 3 13-cis Retino Acid
6 Phase III Study Of Post-Operative Adjuvant Concurrent Chemoradiotherapy For High Risk Oral Cavity Squamous Cell Carcinoma Patients Completed NCT00201383 Phase 3 cisplatin
7 A Phase II/III Study Comparing Acupuncture-like Transcutaneous Electrical Nerve Stimulation (ALTENS) Versus Pilocarpine in Treating Early Radiation-Induced Xerostomia Completed NCT00656513 Phase 2, Phase 3 Pilocarpine
8 Multicentre,A Phase II/III Randomized Study of Adjuvant Anti-Angiogenesis Therapy for Patients of High-Risk Oral Cavity Cancer Terminated NCT00934739 Phase 2, Phase 3 Thalidomide, Celebrex;Cyclophosphamide, Dexamethasone
9 Randomized Phase III Trial on Postoperative Chemoradiation in Combination With Anti EGFR-Antibody Versus Postoperative Chemoradiation in Head and Neck Squamous Cell Carcinomas (HNSCC) With High Risk of Locoregional Recurrence Withdrawn NCT01142414 Phase 3 cisplatin;fluorouracil
10 Phrase II Single Arm Study of Effect of FDG-PET/CT for Simulation and Radiation Treatment Planning in Oral Unknown status NCT03008694 Phase 2
11 A Pilot Study of Combined Modality Therapy for Recurrent Head and Neck Carcinoma Unknown status NCT00003777 Phase 2 amifostine trihydrate;cisplatin;fluorouracil
12 Phase II Study of Preoperative TPF Chemotherapy in Locally Advanced Resectable Oral Cavity Squamous Cell Cancer in Order to Improve the Rate of Pathological Complete Response Unknown status NCT01914900 Phase 2 docetaxel, cisplatin, 5 fluorouracil
13 A Phase II Trial of Paclitaxel (TAXOL) Administered as a Weekly One Hour Infusion in Previously Treated Patients With Advanced Head and Neck Cancer Unknown status NCT00003327 Phase 2 paclitaxel
14 A Pilot Study of Amifostine and Concomitant Cisplatin, Paclitaxel and Radiotherapy in Previously Irradiated, Recurrent Head and Neck Cancer Unknown status NCT00003251 Phase 1, Phase 2 amifostine trihydrate;cisplatin;paclitaxel
15 A Phase I/II Study Using Cisplatin and Gemcitabine (Gemzar) for Advanced Head and Neck Cancer (Squamous Cell Carcinoma) Unknown status NCT00003182 Phase 1, Phase 2 cisplatin;gemcitabine hydrochloride
16 CETUXIMAB Given for 3 Weeks as Neoadjuvant Treatment Followed by 6 Weeks of Cetuximab+RT Post Surgery in Locally Advanced Squamous Cell Carcinoma of the Tongue ; A NEW PARADIGM OF TREATMENT Unknown status NCT01760811 Phase 1, Phase 2 Erbitux,merck serono
17 Health and Economic Outcomes of Two Different Follow up Strategies in Effectively Cured Advanced Head and Neck Cancer Unknown status NCT02262221 Phase 2
18 Radiation Therapy in Combination With Indinavir / Ritonavir (Crixivan / Norvir) for the Treatment of Brain Metastases: a Randomized Phase II Study Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
19 A Preoperative Window of Opportunity Study to Assess the Modulation of Biomarkers in the Primary Tumor Site of Patients With Resectable Oral Cavity Cancer (OCC) Randomized to Receive Preoperative Treatment With PF-00299804 Completed NCT01116843 Phase 1, Phase 2 PF-00299804
20 Pilot Study for the Diagnosis of Head and Neck Cancer: Photofrin and Visible Light Completed NCT00002964 Phase 2 porfimer sodium
21 Efficacy of Implant-Supported Maxillofacial Prostheses Completed NCT00006341 Phase 2
22 Hyperfractionated Radiotherapy With Concomitant Fluorouracil and Hydroxurea for Intermediate Stage Cancer of the Head and Neck Completed NCT00002951 Phase 2 fluorouracil;hydroxyurea
23 A Phase 2, Open-label, Proof-of-concept Study to Assess the Ability to Detect Tumours and Angiogenesis Via the Expression of ανβ3/5 Integrin Receptors by [18F]AH-111585 PET Imaging Completed NCT00565721 Phase 2 Fluciclatide Injection - (AH111585 (F18))
24 Efficacy Evaluation of the Combination of Valproic Acid and Standard Platinum-based Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Completed NCT01695122 Phase 2 Valproic Acid
25 Phase II Double-Blind, Placebo Controlled, Randomized Study Of Celecoxib, A Selective COX-2 Inhibitor, In Oral Premalignant Lesions Completed NCT00014404 Phase 2 celecoxib
26 Do Dietary Supplements of Zinc Reduce Serum Cadmium Levels in Smokers? Completed NCT00376987 Phase 2
27 A Phase IIb Cancer Prevention Trial of Celecoxib, a Selective COX-2 Inhibitor, in Oral Leukoplakia Completed NCT00101335 Phase 2 celecoxib
28 A Randomized, Double Blind, Placebo-Controlled Phase II Clinical Trial of N(4-Hydroxy-phenyl)Retinamide (Fenretinide, 4HPR) in Oral Leukoplakia Completed NCT00004161 Phase 2 fenretinide;Placebo
29 Celecoxib In Biomarker Modulation Of Oral Precancerous Lesions: A Pilot Study Completed NCT00052611 Phase 2 Celecoxib
30 Physiotherapy Versus no Physiotherapy to Patients Suffering From Head and Neck Cancer Undergoing Radiotherapy Treatment Completed NCT00780312 Phase 2
31 Bowman Birk Inhibitor Concentrate and Oral Leukoplakia: A Randomized Phase IIb Trial Completed NCT00330382 Phase 2 Bowman-Birk inhibitor concentrate
32 Clinical Protocol for Wild Type p53 Gene Induction in Premalignancies of Squamous Epithelium of the Oral Cavity and Oral Pharynx Via an Adenoviral Vector [NCI Supplied Agent Ad-p53, (INGN 201) (Advexin®) NSC 683550, IND# 7135] Completed NCT00064103 Phase 1, Phase 2
33 A Phase II Multi-Center Study of Concomitant Cetuximab and Cisplatin With Re-Irradiation Using Intensity-Modulated Radiotherapy in Patients With Recurrent Squamous Cell Carcinoma of the Head-and-Neck Completed NCT00833261 Phase 2 cetuximab;cisplatin;Nab-Paclitaxel
34 Phase II Study of Single-Agent Cetuximab for Treatment of High-Risk Pre-malignant Upper Aerodigestive Lesions Completed NCT00524017 Phase 2
35 A Phase II Study of the Effects of Extended Pre-Cessation Bupropion for Smoking Cessation Completed NCT00534001 Phase 2 bupropion hydrochloride
36 A Randomized Multicenter Phase II Study Using (2-1[Heyloxyethyl]-2-Devinylpyropheophorbide-a) (HPPH) With PDT Versus Standard of Care Surgery for Patients With T1/T2 N0 Squamous Cell Carcinoma of the Oral Cavity Recruiting NCT03090412 Phase 2 HPPH;Photodynamic Therapy
37 Phase II Trial of Nivolumab, an Anti-PD-1 Monoclonal Antibody, as a Novel Neoadjuvant Pre-Surgical Therapy for Locally Advanced Oral Cavity Cancer Recruiting NCT03021993 Phase 2 Nivolumab
38 A Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Efficacy of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence in HLA-A2+ Patients With High-Risk Squamous Cell Carcinoma of the Oral Cavity Recruiting NCT02873819 Phase 2 GL-0817;Hiltonol;Sargramostim;cyclophosphamide;Placebo
39 Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity Recruiting NCT02919683 Phase 2 Nivolumab;Ipilimumab
40 A Randomized, Phase II Study of Ficlatuzumab With or Without Cetuximab in Patients With Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Recruiting NCT03422536 Phase 2 Ficlatuzumab
41 A Phase II Study of Maintenance Tegafur-uracil in Patients With Squamous Cell Carcinoma of Oral Cavity With Extracapsular Spreading of Lymph Nodes Recruiting NCT03121313 Phase 2 tegafur-uracil
42 The LATENT Trial: Lytic Activation To Enhance Neoantigen-directed Therapy A Study to Evaluate the Feasibility and Efficacy of the Combined Use of Avelumab With Valproic Acid for the Treatment of Virus-associated Cancer Recruiting NCT03357757 Phase 2 Valproic Acid
43 Phase II Non-Randomised Controlled Trial Of Concomitant Immune Check Point Inhibitor With Radiotherapy And Chemotherapy Or Cetuximab In Advanced Non Metastatic Head And Neck Cancer Recruiting NCT03532737 Phase 2 Pembrolizumab
44 A Randomized Phase 2 Trial of Neoadjuvant and Adjuvant Therapy With the IRX 2 Regimen in Patients With Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral Cavity Active, not recruiting NCT02609386 Phase 2 Cyclophosphamide;Indomethacin;Omeprazole
45 Phase I Neo-Adjuvant Nivolumab + IRX-2 Followed by Surgery for Resectable Oral Cavity Cancer or HPV-Associated Oropharynx Cancer Not yet recruiting NCT03575234 Phase 1, Phase 2 Cyclophosphamide
46 A Phase II Open-label, Single Arm Study to Evaluate the Efficacy of Sintilimab(IBI 308) to Prevent High-risk Oral Premalignant Lesions Cancerization Not yet recruiting NCT04065737 Phase 2 Sintilimab
47 NICO - CA209-891: Neoadjuvant and Adjuvant Nivolumab as Immune Checkpoint Inhibition in Oral Cavity Cancer Not yet recruiting NCT03721757 Phase 2
48 Open Label Single Arm Phase Ib-II Study of Pre-operative IPH2201 in Patients With Locally Advanced Resectable Squamous Cell Carcinoma of the Oral Cavity Terminated NCT02331875 Phase 1, Phase 2 IPH2201
49 A Single Arm, Phase II Study to Determine the Safety and Efficacy of 4-HPRN-(4-Hydroxyphenyl) Retinamide for Treating Oral Intraepithelial Neoplasia Terminated NCT00003223 Phase 2 fenretinide
50 Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Carcinoma of the Head and Neck Terminated NCT00003489 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)

Search NIH Clinical Center for Oral Cavity Cancer

Genetic Tests for Oral Cavity Cancer

Anatomical Context for Oral Cavity Cancer

MalaCards organs/tissues related to Oral Cavity Cancer:

41
Lymph Node, Tongue, Breast, Lung, Neutrophil, Testes, Prostate

The Foundational Model of Anatomy Ontology organs/tissues related to Oral Cavity Cancer:

19
The

Publications for Oral Cavity Cancer

Articles related to Oral Cavity Cancer:

(show top 50) (show all 839)
# Title Authors PMID Year
1
A Phase 1 Study of Afatinib in Combination with Postoperative Radiation Therapy with and Without Weekly Docetaxel in Intermediate- and High-Risk Patients with Resected Squamous Cell Carcinoma of the Head and Neck. 38
31082494 2019
2
Delays in oral cavity cancer. 38
30878273 2019
3
Does Clearance of Positive Margins Improve Local Control in Oral Cavity Cancer? A Meta-analysis. 38
30912991 2019
4
Second primary cancers in patients with oral cavity cancer included in the Korea Central Cancer Registry. 38
31345385 2019
5
What is the oncologic safety of using the submental flap to reconstruct oral cavity cancer defects? 38
31424567 2019
6
Postoperative wound infections, neutrophil-to-lymphocyte ratio, and cancer recurrence in patients with oral cavity cancer undergoing surgical resection. 38
31421467 2019
7
Evaluation of early oral cavity cancer treatment quality at a single institution. 38
30408196 2019
8
The economic burden of oral squamous cell carcinoma in Australia. 38
31177557 2019
9
Time patterns of recurrence and second primary tumors in a large cohort of patients treated for oral cavity cancer. 38
31400079 2019
10
Oral Cavity Cancer in the Indian Subcontinent - Challenges and Opportunities. 38
31174947 2019
11
Incidence trends for upper aerodigestive tract cancers in rural United States counties. 38
30843640 2019
12
Functional and molecular effects of a green tea constituent on oral cancer cells. 38
31188490 2019
13
Extracapsular extension in oral cavity cancers-predictive factors and impact on recurrence pattern and survival. 38
31003838 2019
14
Prognostic determinants of locally advanced buccal mucosa cancer: Do we need to relook the current staging criteria? 38
31345393 2019
15
Tongue function and its influence on masticatory performance in patients treated for oral cancer: a five-year prospective study. 38
31273502 2019
16
Cancer stem cell self-renewal as a therapeutic target in human oral cancer. 38
30936460 2019
17
Body Image Disturbance in Surgically Treated Head and Neck Cancer Patients: A Prospective Cohort Pilot Study. 38
30857488 2019
18
All-Exon TP53 Sequencing and Protein Phenotype Analysis Accurately Predict Clinical Outcome after Surgical Treatment of Head and Neck Squamous Cell Carcinoma. 38
30900104 2019
19
Tumor Depth of Invasion (Tumor > 4 cm/Depth > 10 mm and Depth > 20 mm) and Through Cortex/Skin Invasion are Both Valid Criteria for Classifying Tumors as pT4a in AJCC 2018 Oral Cavity Cancer Staging System. 38
31264118 2019
20
Somatic Mitochondrial Mutations in Oral Cavity Cancers among Senegalese Patients. 38
31350985 2019
21
Relocation of inadequate resection margins in the wound bed during oral cavity oncological surgery: A feasibility study. 38
30706624 2019
22
Role of Smoking-Mediated Molecular Events in the Genesis of Oral Cancers. 38
31345084 2019
23
Not CD68 but stabilin-1 expression is associated with the risk of recurrence in patients with oral cavity squamous cell carcinoma. 38
30652402 2019
24
Early Postoperative Oral Exercise Improves Swallowing Function Among Patients With Oral Cavity Cancer: A Randomized Controlled Trial. 38
31088304 2019
25
Prognostic implications of stromal hyaluronic acid protein expression in resected oropharyngeal and oral cavity cancers. 38
31352717 2019
26
Management of the Neck in Squamous Cell Carcinoma of the Oral Cavity and Oropharynx: ASCO Clinical Practice Guideline. 38
30811281 2019
27
Association of Oral Human Papillomavirus DNA Persistence With Cancer Progression After Primary Treatment for Oral Cavity and Oropharyngeal Squamous Cell Carcinoma. 38
31046104 2019
28
Effect of Hypofractionated, Palliative Radiotherapy on Quality of Life in Late-Stage Oral Cavity Cancer: A Prospective Clinical Trial. 38
31413453 2019
29
Increased risk of larynx cancer in patients with gastroesophageal reflux disease from a national sample cohort. 38
30884136 2019
30
The profound oral cavity cancer burden in the United States Commonwealth of the Northern Mariana Islands: A global health opportunity. 38
31351740 2019
31
Early oral cavity cancer: The prognostic factors and impact of adjuvant radiation on survival. 38
31339609 2019
32
Impact of physical and psychosocial dysfunction on return to work in survivors of oral cavity cancer. 38
31291694 2019
33
Utility of CT and MRI in assessment of mandibular involvement in oral cavity cancer. 38
31334484 2019
34
Does anatomic subsite influence oral cavity cancer mortality? A SEER database analysis. 38
30408182 2019
35
Inclusion of Neck Level IV in Treatment of Patients With Clinically Node-Negative Oral Cavity Cancer. 38
31070695 2019
36
Consumption of Minimally Processed Foods as Protective Factors in the Genesis of Squamous Cell Carcinoma of the Head and Neck in Brazil (P05-032-19). 38
31224122 2019
37
Near-infrared fluorescence imaging improves the nodal yield in neck dissection in oral cavity cancer - A randomized study. 38
31307814 2019
38
Metabolic tumor volume and total lesion glycolysis predict tumor progression and survival after salvage surgery for recurrent oral cavity squamous cell carcinoma. 38
30675738 2019
39
The oral cavity tumor thickness: Measurement accuracy and consequences for tumor staging. 38
31227341 2019
40
Assessment of the Rate of Skip Metastasis to Neck Level IV in Patients With Clinically Node-Negative Neck Oral Cavity Squamous Cell Carcinoma: A Systematic Review and Meta-analysis. 38
31070693 2019
41
Measuring Depth of Invasion in Early Squamous Cell Carcinoma of the Oral Tongue: Positive Deep Margin, Extratumoral Perineural Invasion, and Other Challenges. 38
29700721 2019
42
Functional outcomes of the modified submandibular gland transfer procedure. 38
31087663 2019
43
Attributable fraction for multiple risk factors: Methods, interpretations, and examples. 38
31074326 2019
44
Can Early Dental Extractions Reduce Delays in Postoperative Radiation for Patients With Advanced Oral Cavity Carcinoma? 38
31228426 2019
45
Prognostic performance of the American Joint Committee on Cancer 8th edition of the TNM staging system in patients with early oral tongue cancer. 38
30537405 2019
46
Oral tongue cancer in a patient with hereditary nonpolyposis colorectal cancer: A case report and review of the literature. 38
30885722 2019
47
Clinical Implications of Tumor-Associated Tissue Eosinophilia in Tongue Squamous Cell Carcinoma. 38
30098046 2019
48
Analysis of Process-Related Quality Metrics and Survival of Patients with Oral Cavity Squamous Cell Carcinoma. 38
31060452 2019
49
Identification and characterization of novel human papillomaviruses in oral rinse samples from oral cavity and oropharyngeal cancer patients. 38
31129167 2019
50
Impact of postoperative radiation therapy for deeply invasive oral cavity cancer upstaged to stage III. 38
30773733 2019

Variations for Oral Cavity Cancer

ClinVar genetic disease variations for Oral Cavity Cancer:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 PTEN NM_000314.7(PTEN): c.388C> G (p.Arg130Gly) single nucleotide variant Pathogenic rs121909224 10:89692904-89692904 10:87933147-87933147
2 PIK3CA NM_006218.4(PIK3CA): c.3139C> T (p.His1047Tyr) single nucleotide variant Pathogenic rs121913281 3:178952084-178952084 3:179234296-179234296
3 PIK3CA NM_006218.4(PIK3CA): c.3145G> C (p.Gly1049Arg) single nucleotide variant Likely pathogenic rs121913277 3:178952090-178952090 3:179234302-179234302

Expression for Oral Cavity Cancer

Search GEO for disease gene expression data for Oral Cavity Cancer.

Pathways for Oral Cavity Cancer

Pathways related to Oral Cavity Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 59)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.87 VEGFA TNFRSF10B SOX2 PTEN GDF15 FADD
2
Show member pathways
13.4 TNFRSF10B TLR2 PTEN GDF15 FADD ERBB2
3
Show member pathways
13.31 TNFRSF10B PTEN GDF15 ERBB2 EGFR CASP8
4
Show member pathways
12.93 TNFRSF10B PIK3CA FADD EGFR EDNRB CASP8
5
Show member pathways
12.89 VEGFA PTEN PIK3CA ERBB2 EGFR
6
Show member pathways
12.88 VEGFA TNFRSF10B PTEN PIK3CA FADD EGFR
7
Show member pathways
12.87 VEGFA TLR2 PTEN PIK3CA FADD EGFR
8
Show member pathways
12.84 VEGFA PTEN PIK3CA ERBB2 EGFR BAX
9
Show member pathways
12.79 TNFRSF10B PIK3CA MCL1 FADD CASP8 BAX
10
Show member pathways
12.73 PTEN PIK3CA GSTM1 ERBB2 EGFR BAX
11
Show member pathways
12.69 VEGFA TLR2 PTEN PIK3CA MCL1 FADD
12
Show member pathways
12.66 VEGFA PTEN PIK3CA ERBB2 EGFR BAX
13
Show member pathways
12.58 VEGFA TNFRSF10B TLR2 PIK3CA FADD CASP8
14
Show member pathways
12.57 VEGFA PIK3CA ERBB2 EGFR
15
Show member pathways
12.54 VEGFA TNFRSF10B PTEN PIK3CA FADD EGFR
16
Show member pathways
12.49 PTEN PIK3CA ERBB2 EGFR
17 12.48 VEGFA PTEN PIK3CA MCL1 ERBB2 EGFR
18
Show member pathways
12.47 PTEN PIK3CA ERBB2 BAX
19
Show member pathways
12.42 PIK3CA ERBB2 EGFR CASP8 BAX
20
Show member pathways
12.38 TNFRSF10B PTEN CASP8 BAX
21 12.38 VEGFA PTEN PIK3CA GSTM1 FADD ERBB2
22
Show member pathways
12.3 TNFRSF10B PIK3CA FADD CASP8
23
Show member pathways
12.26 TNFRSF10B PTEN CASP8 BAX
24 12.26 VEGFA TLR2 PIK3CA ERBB2 EGFR
25 12.24 TLR2 FADD CASP8 BAX
26
Show member pathways
12.23 TNFRSF10B FADD CASP8 BAX
27 12.19 VEGFA TLR2 EGFR BAX
28
Show member pathways
12.19 PTEN PIK3CA ERBB2 EGFR BAX
29
Show member pathways
12.13 PTEN PIK3CA ERBB2 EGFR
30 12.11 TNFRSF10B MCL1 GDF15 FADD CASP8 BAX
31
Show member pathways
12.1 PTEN PIK3CA ERBB2 EGFR
32
Show member pathways
12.09 TNFRSF10B PIK3CA GDF15 EGFR BAX
33 12.09 PTEN PIK3CA ERBB2 EGFR BAX
34
Show member pathways
12.07 SOD2 PTEN PIK3CA EGFR
35 11.99 VEGFA PTEN FADD EGFR CASP8 BAX
36
Show member pathways
11.95 TLR2 PIK3CA ERBB2 EGFR CASP8
37 11.91 VEGFA PIK3CA ERBB2 EGFR
38 11.9 VEGFA PIK3CA BAX
39 11.89 SOD2 PTEN PIK3CA ERBB2 BAX
40
Show member pathways
11.86 VEGFA ERBB2 EGFR
41 11.85 PTEN PIK3CA BAX
42 11.85 TNFRSF10B PTEN MCL1 GDF15 EGFR BAX
43
Show member pathways
11.81 PIK3CA CASP8 BAX
44
Show member pathways
11.78 MCL1 FADD CASP8 BAX
45 11.75 VEGFA ERBB2 EGFR
46 11.7 PTEN PIK3CA ERBB2
47 11.66 PTEN PIK3CA ERBB2 EGFR
48 11.57 MCL1 EGFR BAX
49 11.53 EGFR CYP1A1 BAX
50 11.53 VEGFA EGFR CYP1A1

GO Terms for Oral Cavity Cancer

Cellular components related to Oral Cavity Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell body GO:0044297 9.58 TLR2 FADD CASP8
2 cytoplasm GO:0005737 9.53 VEGFA TLR2 SOX2 PTEN PIK3CA MCL1
3 death-inducing signaling complex GO:0031264 9.37 FADD CASP8
4 membrane raft GO:0045121 9.35 TLR2 FADD EGFR EDNRB CASP8
5 ripoptosome GO:0097342 9.32 FADD CASP8
6 CD95 death-inducing signaling complex GO:0031265 9.26 FADD CASP8
7 Bcl-2 family protein complex GO:0097136 9.16 MCL1 BAX

Biological processes related to Oral Cavity Cancer according to GeneCards Suite gene sharing:

(show all 39)
# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.98 VEGFA SOX2 PIK3CA MCL1
2 apoptotic process GO:0006915 9.98 TNFRSF10B TLR2 PTEN MCL1 FADD CASP8
3 negative regulation of apoptotic process GO:0043066 9.95 VEGFA PTEN MCL1 EGFR EDNRB
4 positive regulation of protein phosphorylation GO:0001934 9.91 VEGFA ERBB2 EGFR EDNRB
5 positive regulation of protein kinase B signaling GO:0051897 9.88 PIK3CA GDF15 ERBB2 EGFR
6 response to lipopolysaccharide GO:0032496 9.88 TLR2 EDNRB CYP1A1 CASP8
7 response to toxic substance GO:0009636 9.85 TLR2 CYP1A1 BAX
8 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.83 VEGFA PIK3CA EGFR
9 liver development GO:0001889 9.83 PIK3CA EGFR CYP1A1
10 response to organic cyclic compound GO:0014070 9.83 PTEN EGFR EDNRB CYP1A1
11 response to wounding GO:0009611 9.81 SOX2 CYP1A1 BAX
12 apoptotic signaling pathway GO:0097190 9.8 FADD CASP8 BAX
13 positive regulation of MAP kinase activity GO:0043406 9.8 VEGFA ERBB2 EGFR
14 positive regulation of epithelial cell proliferation GO:0050679 9.79 VEGFA ERBB2 EGFR
15 aging GO:0007568 9.77 PTEN EDNRB CYP1A1
16 cell proliferation GO:0008283 9.77 PTEN ERCC1 EGFR CYP1A1 BAX
17 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.76 TNFRSF10B FADD CASP8 BAX
18 extrinsic apoptotic signaling pathway GO:0097191 9.74 FADD CASP8 BAX
19 cell surface receptor signaling pathway GO:0007166 9.73 TNFRSF10B FADD ERBB2 EGFR EDNRB CASP8
20 positive regulation of MAPK cascade GO:0043410 9.71 SOX2 GDF15 ERBB2
21 cellular response to mechanical stimulus GO:0071260 9.71 TNFRSF10B FADD EGFR CASP8
22 negative regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902042 9.69 TNFRSF10B FADD CASP8
23 negative regulation of phagocytosis GO:0050765 9.68 TLR2 PTEN
24 positive regulation of macrophage differentiation GO:0045651 9.67 FADD CASP8
25 activation of cysteine-type endopeptidase activity GO:0097202 9.67 FADD CASP8
26 extrinsic apoptotic signaling pathway in absence of ligand GO:0097192 9.67 MCL1 FADD BAX
27 regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043281 9.66 SOX2 BAX
28 response to arsenic-containing substance GO:0046685 9.66 PTEN CYP1A1
29 ERBB2 signaling pathway GO:0038128 9.65 PIK3CA ERBB2 EGFR
30 toll-like receptor 3 signaling pathway GO:0034138 9.64 FADD CASP8
31 death-inducing signaling complex assembly GO:0071550 9.63 FADD CASP8
32 regulation of apoptotic process GO:0042981 9.63 TNFRSF10B MCL1 GDF15 FADD CASP8 BAX
33 regulation of necroptotic process GO:0060544 9.61 FADD CASP8
34 negative regulation of ERBB signaling pathway GO:1901185 9.6 ERBB2 EGFR
35 activation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway GO:0097296 9.56 CASP8 BAX
36 regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902041 9.5 TNFRSF10B FADD CASP8
37 extrinsic apoptotic signaling pathway via death domain receptors GO:0008625 9.26 TNFRSF10B FADD CASP8 BAX
38 TRAIL-activated apoptotic signaling pathway GO:0036462 8.8 TNFRSF10B FADD CASP8
39 nervous system development GO:0007399 10.04 VEGFA PTEN ERBB2 EDNRB BAX

Molecular functions related to Oral Cavity Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 platelet-derived growth factor receptor binding GO:0005161 9.43 VEGFA PTEN
2 protein heterodimerization activity GO:0046982 9.43 VEGFA TLR2 MCL1 ERBB2 EGFR BAX
3 death receptor binding GO:0005123 9.4 FADD CASP8
4 identical protein binding GO:0042802 9.28 VEGFA TLR2 SOD2 PTEN FADD ERBB2
5 BH3 domain binding GO:0051434 9.26 MCL1 BAX
6 death effector domain binding GO:0035877 9.16 FADD CASP8
7 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.07 PIK3CA
8 protein binding GO:0005515 10.25 VEGFA TNFRSF10B TLR2 SOX2 PTEN PIK3CA

Sources for Oral Cavity Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....